How to Help Your Patients Find Leqvio in Stock: A Provider's Guide

Leqvio (inclisiran) is a powerful tool in the lipid management arsenal — but patients frequently report confusion and frustration when trying to access it. As a prescriber, your guidance and proactive support make a critical difference in whether a patient actually gets their injection. This guide covers the key steps to help your patients access Leqvio smoothly in 2026.

Why Do Patients Struggle to Access Leqvio?

Leqvio's physician-administered, buy-and-bill model creates a multi-step process that patients are not accustomed to. Unlike a standard oral medication, there is no pharmacy transaction — the patient depends entirely on:

1. A provider who stocks or can quickly source the drug
2. Insurance prior authorization approval
3. A scheduled appointment for the injection

Any delay in any one of these steps can delay the patient's first dose by weeks or months. Some patients give up and go without treatment when the path forward isn't clearly communicated.

Step 1: Confirm You Can Administer It In Your Practice (or Make a Referral)

Before prescribing Leqvio, clarify whether your practice can administer it. If yes, ensure your staff knows the ordering process through your specialty distributor. If not, have a referral pathway ready — ideally a cardiologist, lipid clinic, or infusion center that regularly stocks and administers Leqvio.

Telling a patient "you've been prescribed Leqvio" without telling them where to go to get it injected is a common gap. Clear referral communication prevents this.

Step 2: Submit Prior Authorization Proactively and Completely

Prior authorization is required by virtually all commercial payers and many Medicare Advantage plans. To maximize approval speed and minimize denials:

• Submit the PA request the same day you prescribe, not after the patient calls back.
• Include the patient's most recent LDL-C value (within the past 6 months if possible).
• Document current statin therapy or statin intolerance with specific trials documented.
• Include the diagnosis code for HeFH (E78.01) or ASCVD (I25.10, etc.) as appropriate.
• If denied, request a peer-to-peer review immediately — most denials on clinically appropriate patients are overturned at peer-to-peer.

Step 3: Enroll Your Patient in the Leqvio Co-Pay Program Before the First Dose

For commercially insured patients, the Leqvio Co-Pay Program can reduce out-of-pocket costs to as little as $0. No financial documentation is required to enroll. Encourage your team to complete enrollment during the PA process or at the time of scheduling.

For Medicare patients, the Novartis Patient Assistance Foundation may provide support for eligible low-income patients. Patients can also call the Leqvio Service Center at 1-833-537-8462.

Step 4: Give Patients Clear Instructions on What Happens Next

At the point of prescribing, provide every patient with:

• The name and address of the clinic where they'll receive the injection
• Timeline: when to expect the PA decision and when to follow up if they don't hear back
• The Leqvio Service Center number (1-833-537-8462) for any questions or delays
• Their first three appointment dates: initial dose, 3-month dose, then every 6 months

Step 5: Use medfinder When Patients Report Access Problems

When a patient reports they can't find where to get their injection, medfinder for providers can locate clinics near the patient that stock Leqvio and have availability. This is particularly useful for patients in rural areas or those who have moved to a new region and need to find a new administering provider quickly.

Monitoring and Follow-Up

After initiating Leqvio, monitor LDL-C approximately 8–12 weeks after each dose to assess response. If a patient misses a dose by more than 3 months, restart the full dosing schedule. Consider setting calendar reminders in your EHR system or patient portal to proactively schedule upcoming injection appointments.

For a clinical overview of Leqvio availability and prior auth in 2026, see our Leqvio provider shortage update.